Details for New Drug Application (NDA): 201806
✉ Email this page to a colleague
The generic ingredient in EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE is emtricitabine; tenofovir disoproxil fumarate. There are eighteen drug master file entries for this compound. Thirty-one suppliers are listed for this compound. Additional details are available on the emtricitabine; tenofovir disoproxil fumarate profile page.
Summary for 201806
Tradename: | EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE |
Applicant: | Hetero Labs Ltd Iii |
Ingredient: | emtricitabine; tenofovir disoproxil fumarate |
Patents: | 0 |
Pharmacology for NDA: 201806
Mechanism of Action | Nucleoside Reverse Transcriptase Inhibitors |
Suppliers and Packaging for NDA: 201806
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE | emtricitabine; tenofovir disoproxil fumarate | TABLET;ORAL | 201806 | ANDA | Camber Pharmaceuticals, Inc. | 31722-560 | 31722-560-30 | 30 TABLET, FILM COATED in 1 BOTTLE (31722-560-30) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 200MG;300MG | ||||
Approval Date: | Oct 7, 2021 | TE: | AB | RLD: | No |
Complete Access Available with Subscription